Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials

Background: B-cell leukemia/lymphoma-2 (BCL-2) protein is an important part of apoptotic pathway, which is overexpressed in chronic lymphocytic leukemia cells, non-Hodgkin lymphoma cells, and myeloma cells. Venetoclax (ABT-199/GDC-0199) is a highly selective bioavailable inhibitor of BCL-2 protein,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qingfang, Cheng, Li, Shen, Kai, Jin, Hongyu, Li, Hui, Cheng, Yuan, Ma, Xuelei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598635/
https://www.ncbi.nlm.nih.gov/pubmed/31293422
http://dx.doi.org/10.3389/fphar.2019.00697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598635/
https://www.ncbi.nlm.nih.gov/pubmed/31293422
http://dx.doi.org/10.3389/fphar.2019.00697

Ejemplares similares